tirzepatide by eli lilly (LLY) Gets Nod to Launch Weight-Loss Drug Mounjaro in Hong Kong Eli Lilly Introduces New Zepbound

Philis-Tsimikas A, Billings L, Busch R

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015:648108

Why ARA-290 Is Different from Erythropoietin Erythropoietin: Increases red blood cell production Raises hematocrit Increases thrombosis risk at high levels ARA-290: Does not affect red blood cells Does not raise hematocrit Does not increase clotting risk This distinction makes ARA-290 suitable for chronic use in inflammatory and neurologic conditions , where EPO would be unsafe

Its also important for providers to advise patients about on how to measure doses accurately

1 GLP-1 RA=glucagon-like peptide-1 receptor agonist Victoza efficacy and safety data for patients with type 2 diabetes Interested in CV outcomes for patients also with established cardiovascular disease

Why is there so much variety in what a patient ends up paying for these drugs